1
|
Mori K, Horinouchi M, Domitsu A, Shimotahira T, Soutome S, Yamaguchi T, Oho T. Proper oral hygiene protocols decreased inflammation of gingivitis in a patient during chemotherapy with bevacizumab: a case report. Clin Case Rep 2017; 5:1352-1357. [PMID: 28781858 PMCID: PMC5538079 DOI: 10.1002/ccr3.1034] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Revised: 03/28/2017] [Accepted: 05/08/2017] [Indexed: 11/10/2022] Open
Abstract
The case is a woman who had a diagnosis of ovarian cancer and endometrial cancer. After surgical therapy, platinum-based adjuvant treatment was performed, followed by additional bevacizumab administration. Because considerable gingivitis appeared, a proper approach for oral hygiene was performed. As a result, the symptom was reduced considerably.
Collapse
Affiliation(s)
- Kazuyo Mori
- Division of Clinical Engineering Kagoshima University Hospital Kagoshima Japan
| | - Miho Horinouchi
- Division of Clinical Engineering Kagoshima University Hospital Kagoshima Japan
| | - Ayumi Domitsu
- Division of Clinical Engineering Kagoshima University Hospital Kagoshima Japan
| | - Takako Shimotahira
- Division of Clinical Engineering Kagoshima University Hospital Kagoshima Japan
| | - Sakiko Soutome
- Perioperative Oral Management Center Nagasaki University Hospital Nagasaki Japan
| | - Taihei Yamaguchi
- Department of Preventive Dentistry Research Field in Dentistry, Medical and Dental Sciences Area Kagoshima University Kagoshima Japan
| | - Takahiko Oho
- Department of Preventive Dentistry Research Field in Dentistry, Medical and Dental Sciences Area Kagoshima University Kagoshima Japan
| |
Collapse
|
2
|
Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, Marchetti P, Barba M, Magnolfi E, Maugeri‐Saccà M, Rossi E, Sini V, Grassadonia A, Pellegrini D, Astone A, Nisticò C, Angelini F, Vaccaro A, Pellegrino A, De Angelis C, Palleschi M, Moscetti L, Bertolini I, Buglioni S, Giordano A, Pizzuti L, Vici P. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. J Cell Physiol 2017; 232:1571-1578. [PMID: 27861874 PMCID: PMC6220933 DOI: 10.1002/jcp.25685] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Accepted: 11/10/2016] [Indexed: 01/04/2023]
Abstract
Bevacizumab in combination with taxanes in HER2-negative metastatic breast cancer (MBC) patients has shown improved progression-free survival (PFS), despite the lack of clear overall survival (OS) benefit. We performed a retrospective analysis to evaluate the impact of paclitaxel-bevacizumab and of maintenance therapy with bevacizumab (BM) and endocrine therapy (ET) in the real-world practice. We identified 314 HER2-negative MBC patients treated in 12 cancer centers. Overall, the median PFS and OS were 14 and 40 months, respectively. Among the 254 patients potentially eligible for BM, 183 received BM after paclitaxel discontinuation until progression/toxicity. PFS and OS were improved in patients who had received BM in comparison with those potentially eligible but who did not receive BM (P< 0.0001 and P = 0.001, respectively). Results were confirmed when adjusting for propensity score. Among the 216 hormone-receptor positive patients eligible for BM, a more favorable PFS and OS were observed when maintenance ET was administered (P < 0.0001). Multivariate analysis showed that PS, BM, number of disease sites and maintenance ET were related to PFS, while response and maintenance ET were related to OS. In hormone-receptor positive patients, BM produced a significant PFS and a trend towards OS benefit only in absence of maintenance ET (P = 0.0007 and P = 0.06, respectively). In the triple-negative subgroup, we observed a trend towards a better OS for patients who received BM (P = 0.06), without differences in PFS (P = 0.21). Our results confirmed the efficacy of first-line paclitaxel-bevacizumab in real-world practice; both BM and maintenance ET significantly improved PFS and OS compared to no maintenance therapies. J. Cell. Physiol. 232: 1571-1578, 2017. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
| | | | - Clara Natoli
- Department of Medical, Oral and Biotechnological SciencesCentro Scienze dell’ Invecchiamento e Medicina Traslazionale ‐ CeSI‐MeTChietiItaly
| | - Isabella Sperduti
- Bio‐Statistics Unit, Regina Elena National Cancer InstituteRomeItaly
| | - Alessandra Cassano
- Department of Medical OncologyPoliclinico Universitario A. GemelliRomeItaly
| | | | - Luigi Di Lauro
- Division of Medical Oncology 2Regina Elena National Cancer InstituteRomeItaly
| | - Domenico Sergi
- Division of Medical Oncology 2Regina Elena National Cancer InstituteRomeItaly
| | - Alessandra Fabi
- Division of Medical Oncology 1Regina Elena National Cancer InstituteRomeItaly
| | | | - Paolo Marchetti
- Department of Clinical and Molecular Medicine“Sapienza” University of RomeAzienda Ospedaliera Sant'AndreaRomeItaly
| | - Maddalena Barba
- Division of Medical Oncology 2Regina Elena National Cancer InstituteRomeItaly
- Scientific DirectionRegina Elena National Cancer InstituteRomeItaly
| | | | - Marcello Maugeri‐Saccà
- Division of Medical Oncology 2Regina Elena National Cancer InstituteRomeItaly
- Scientific DirectionRegina Elena National Cancer InstituteRomeItaly
| | - Ernesto Rossi
- Department of Medical OncologyPoliclinico Universitario A. GemelliRomeItaly
| | - Valentina Sini
- Department of Clinical and Molecular Medicine“Sapienza” University of RomeAzienda Ospedaliera Sant'AndreaRomeItaly
| | - Antonino Grassadonia
- Department of Medical, Oral and Biotechnological SciencesCentro Scienze dell’ Invecchiamento e Medicina Traslazionale ‐ CeSI‐MeTChietiItaly
| | - Domenica Pellegrini
- Division of Medical Oncology 1Regina Elena National Cancer InstituteRomeItaly
| | - Antonino Astone
- Department of Medical OncologyPoliclinico Universitario A. GemelliRomeItaly
| | - Cecilia Nisticò
- Division of Medical Oncology 1Regina Elena National Cancer InstituteRomeItaly
| | - Franco Angelini
- Medical Oncology UnitRegina Apostolorum HospitalAlbano, RomeItaly
| | | | | | | | | | - Luca Moscetti
- Medical Oncology Unit, Belcolle HospitalViterboItaly
- Department of Medical and Surgical Sciences for Children and AdultsAzienda Ospedaliero‐Universitaria Policlinico di ModenaModenaItaly
| | - Ilaria Bertolini
- Oncology Unit IAzienda Ospedaliera Universitaria PisanaPisaItaly
| | | | - Antonio Giordano
- Sbarro Institute for Cancer Research and Molecular Medicine and Center for BiotechnologyCollege of Science and TechnologyTemple UniversityPhiladelphiaPennsylvania
| | - Laura Pizzuti
- Division of Medical Oncology 2Regina Elena National Cancer InstituteRomeItaly
| | - Patrizia Vici
- Division of Medical Oncology 2Regina Elena National Cancer InstituteRomeItaly
| |
Collapse
|
3
|
Zambonin V, De Toma A, Carbognin L, Nortilli R, Fiorio E, Parolin V, Pilotto S, Cuppone F, Pellini F, Lombardi D, Pollini GP, Tortora G, Bria E. Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. Expert Opin Biol Ther 2017; 17:497-506. [PMID: 28133971 DOI: 10.1080/14712598.2017.1289171] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
INTRODUCTION Angiogenesis plays a fundamental role in breast cancer (BC) growth, progression and metastatic spread. After the promising introduction of bevacizumab for the treatment of advanced BC, the initial enthusiasm decreased when the FDA withdrew its approval in 2011. Nevertheless, several clinical studies exploring the role of bevacizumab have been subsequently published. Areas covered: The aim of this study is to review the available clinical trials exploring the potential effectiveness of bevacizumab in BC, regardless of the disease setting. Expert opinion: Even if the evidence suggests that bevacizumab must be ruled out from the HER2-positive and adjuvant setting, bevacizumab's benefit remains uncertain in the neoadjuvant setting and in the advanced treatment of HER2-negative patients. In the first setting, the addition of bevacizumab to chemotherapy increased the pathological complete response (pCR) rate in most clinical trials. However, the current absence of evidence that pCR is a trial-level surrogate for survival requires waiting for long-term results. In the advanced setting, all trials showed a benefit in progression-free survival, but not in overall survival, highlighting an increase of adverse events. The lack of predictors of response represents the main unmet need in which future clinical research will undoubtedly invest.
Collapse
Affiliation(s)
- Valentina Zambonin
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| | - Alessandro De Toma
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| | - Luisa Carbognin
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| | - Rolando Nortilli
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| | - Elena Fiorio
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| | - Veronica Parolin
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| | - Sara Pilotto
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| | | | - Francesca Pellini
- b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,d Chirurgia Senologica, Azienda Ospedaliera Universitaria Integrata, A.O.U.I. Breast Surgery Verona , Verona , Italy
| | - Davide Lombardi
- b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,d Chirurgia Senologica, Azienda Ospedaliera Universitaria Integrata, A.O.U.I. Breast Surgery Verona , Verona , Italy
| | - Giovanni Paolo Pollini
- b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,d Chirurgia Senologica, Azienda Ospedaliera Universitaria Integrata, A.O.U.I. Breast Surgery Verona , Verona , Italy
| | - Giampaolo Tortora
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| | - Emilio Bria
- a U.O. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.,b Breast Unit, Azienda Ospedaliera Universitaria Integrata , Verona , Italy
| |
Collapse
|